Innovation of the novel cardiac regeneration therapy using gene introduction-mediated cell conversion into cardiac progenitor cells.

点击翻译按钮获取中文摘要

Recent technologies to reprogram somatic cells into induced pluripotent stem (iPS) cells have been expected as a powerful tool of regeneration therapy for end-staged heart failure. However, duration of iPS cell derivation and the risk of tumorigenesis including teratoma after cell implantation as well as limited efficiency for cardiac differentiation are considered as great barriers against the clinical application of this powerful approach. To overcome these problems, by modifying the reprograming process, here we show the novel alternative strategy which enables us to create cardiac myocytes directly from fibroblasts rapidly and efficiently with a low risk of tumorigenesis. In addition, we established the mouse experimental model to evaluate the effect of this strategy as an innovative cardiac regeneration therapy.